Galanin in Alzheimer disease

Area of Science:

• Neuroscience
• Neurodegenerative Diseases
• Pharmacology

Background:

• Galanin (GAL) and GAL receptors (GALR) are overexpressed in Alzheimer disease (AD) limbic regions linked to cognition.
• The precise impact of GAL overexpression on AD pathogenesis remains unclear.
• GAL's dual role is suggested by its inhibition of cholinergic transmission versus its potential neuroprotective effects.

Purpose of the Study:

• To investigate the functional consequences of GAL and GALR overexpression in Alzheimer disease.
• To explore the potential neuroprotective or detrimental roles of galaninergic signaling in AD.
• To assess the therapeutic potential of targeting GAL receptors for AD treatment.

Main Methods:

• Analysis of GAL and GALR expression in AD-affected brain regions.
• Investigation of GAL's effects on cholinergic transmission and hippocampal long-term potentiation.
• Examination of GAL's influence on protein phosphatase 1 subtype mRNAs in basal forebrain neurons.

Main Results:

• GAL overexpression may exacerbate AD cognitive symptoms by inhibiting cholinergic function.
• GAL expression increases with neuronal injury, suggesting a neuroprotective role.
• Galaninergic hyperinnervation appears to prevent reduced mRNA levels in AD basal forebrain neurons.

Conclusions:

• Galanin signaling presents a complex, dual role in Alzheimer disease.
• GAL may worsen AD by inhibiting cholinergic transmission but also protect neurons.
• Understanding GAL activity in vulnerable brain regions is crucial for developing GALR ligand therapies for AD.